ELCELYX THERAPEUTICS, INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.elcelyx.com
Clinical Trials
6
Active:0
Completed:6
Trial Phases
2 Phases
Phase 1:3
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)β’ Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
3 (50.0%)Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 571
- Registration Number
- NCT02526524
- Locations
- πΊπΈ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈCentral Alabama Research, Birmingham, Alabama, United States
πΊπΈAchieve Clinical Research, LLC, Birmingham, Alabama, United States
Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02291510
Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT01819272
Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01804842
Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: EFB0026 (metformin immediate-release)Drug: EFB0027 (metformin delayed release)
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Elcelyx Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01677299
- Locations
- πΊπΈ
Celerion, Inc., Lincoln, Nebraska, United States
- Prev
- 1
- 2
- Next
News
No news found